Published in J Neurol on June 25, 2007
Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol (1998) 6.30
Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol (2001) 1.56
Physiology of REM sleep, cataplexy, and sleep paralysis. Adv Neurol (1995) 1.02
Changes in the cortical silent period after repetitive magnetic stimulation of cortical motor areas. Exp Brain Res (2000) 0.99
RTMS induces brief events of muscle atonia in patients with narcolepsy. Sleep (2000) 0.89
Intravenous clomipramine decreases excitability of human motor cortex. A study with paired magnetic stimulation. J Neurol Sci (2001) 0.88
Hypocretin (orexin) deficiency in human narcolepsy. Lancet (2000) 7.92
A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med (2000) 7.05
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A (1988) 6.74
HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology (1992) 4.70
Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J (2001) 3.22
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
[Turning the head, an unusual mechanism to compensate for diplopia caused by abduction restriction of one eye]. Ned Tijdschr Geneeskd (2004) 2.65
Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology (1991) 2.59
Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord (2011) 2.53
Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol (2001) 2.47
Syncope in migraine: the population-based CAMERA study. Neurology (2006) 2.33
AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS (1997) 1.97
Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology (1991) 1.85
Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2002) 1.80
Repetitive transcranial magnetic stimulation for Tourette syndrome. Neurology (2002) 1.69
Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. AIDS (1988) 1.68
Effects of the human intestinal flora on germ-free mice. J Appl Bacteriol (1981) 1.64
Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology (2008) 1.60
"On" state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication. Neurology (2012) 1.59
Juvenile Huntington disease. Hum Genet (1986) 1.57
Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol (2001) 1.56
[Initial diagnostic strategy in the case of transient losses of consciousness: the importance of the medical history]. Ned Tijdschr Geneeskd (2003) 1.55
Differential diagnosis of proprioceptive and vestibular deficits using dynamic support-surface posturography. Gait Posture (2001) 1.53
Pros and cons of quitting, self-efficacy, and the stages of change in smoking cessation. J Consult Clin Psychol (1996) 1.52
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52
CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology (2003) 1.50
Weak with laughter. Lancet (1999) 1.49
Single-fiber EMG in familial hemiplegic migraine. Neurology (2004) 1.46
Multi-level approach to anaesthetic effects produced by sevoflurane or propofol in humans: 1. BIS and blink reflex. Br J Anaesth (2007) 1.45
Multi-level approach to anaesthetic effects produced by sevoflurane or propofol in humans: 2. BIS and tetanic stimulus-induced withdrawal reflex. Br J Anaesth (2007) 1.41
Why is the electromyogram in obstetric brachial plexus lesions overly optimistic? Muscle Nerve (1998) 1.40
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ (1989) 1.39
Impairment of trigeminal sensory pathways in cluster headache. Cephalalgia (2003) 1.39
Cerebral correlates of motor imagery of normal and precision gait. Neuroimage (2008) 1.38
Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson's disease. Mov Disord (1996) 1.38
[Repetitive transcranial magnetic stimulation in depression; stimulation of the brain in order to cure the psyche]. Ned Tijdschr Geneeskd (2004) 1.37
[Gait disorders due to neurological conditions]. Ned Tijdschr Geneeskd (2007) 1.37
Functional connectivity of human premotor and motor cortex explored with repetitive transcranial magnetic stimulation. J Neurosci (2002) 1.37
Postural abnormalities to multidirectional stance perturbations in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 1.36
The multiple tasks test. Strategies in Parkinson's disease. Exp Brain Res (2001) 1.36
Age-dependent variations in the directional sensitivity of balance corrections and compensatory arm movements in man. J Physiol (2002) 1.36
CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology (2001) 1.35
International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology (2009) 1.34
The outcome of absence epilepsy: a meta-analysis. Neurology (1996) 1.34
Intrathecal synthesis of antibodies to HTLV-III in patients without AIDS or AIDS related complex. Br Med J (Clin Res Ed) (1986) 1.30
Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. J Clin Microbiol (2001) 1.26
Motor imagery of gait: a quantitative approach. Exp Brain Res (2007) 1.26
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24
Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology (2004) 1.24
Systematic review of quantitative clinical gait analysis in patients with dementia. Z Gerontol Geriatr (2004) 1.23
Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses (2001) 1.22
Trunk sway measurements during stance and gait tasks in Parkinson's disease. Gait Posture (2005) 1.22
Differential progression of proprioceptive and visual information processing deficits in Parkinson's disease. Eur J Neurosci (2005) 1.18
Repetitive CMAPs: mechanisms of neural and synaptic genesis. Muscle Nerve (1996) 1.18
Diagnostic value of history taking in reflex syncope. Clin Auton Res (2004) 1.17
Antibody response to a synthetic peptide covering a LAV-1/HTLV-IIIB neutralization epitope and disease progression. AIDS (1989) 1.16
IgG response to human immunodeficiency virus in experimentally infected chimpanzees mimics the IgG response in humans. J Infect Dis (1987) 1.14
Allied health care interventions and complementary therapies in Parkinson's disease. Parkinsonism Relat Disord (2007) 1.13
EFNS guidelines on management of narcolepsy. Eur J Neurol (2006) 1.13
Myoclonus-dystonia: clinical and genetic evaluation of a large cohort. J Neurol Neurosurg Psychiatry (2008) 1.11
Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans. J Clin Endocrinol Metab (2002) 1.11
A 4-base pair deletion in the mitochondrial cytochrome b gene associated with parkinsonism/MELAS overlap syndrome. Ann Neurol (1999) 1.10
Evolution of epilepsy and EEG findings in Angelman syndrome. Epilepsia (1997) 1.10
Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology (2002) 1.08
Spontaneous food choice in narcolepsy. Sleep (1996) 1.07
Weight loss in neurodegenerative disorders. J Neurol (2009) 1.06
The "bicycle sign" for atypical parkinsonism. Lancet (2011) 1.06
One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AG. J Clin Microbiol (2001) 1.06
Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm Park Dis Dement Sect (1993) 1.05
Ten steps to identify atypical parkinsonism. J Neurol Neurosurg Psychiatry (2006) 1.04
Review of first trial responses in balance control: influence of vestibular loss and Parkinson's disease. Hum Mov Sci (2011) 1.02
Convergence of circadian and sleep regulatory mechanisms on hypocretin-1. Neuroscience (2004) 1.01
Clinical aspects of multifocal or generalized tonic dystonia in reflex sympathetic dystrophy. Neurology (2001) 1.01
Interobserver variation in the interpretation of SSEPs in anoxic-ischaemic coma. Clin Neurophysiol (2006) 1.01
Hyponatraemia due to amantadine hydrochloride and L-dopa/carbidopa. Lancet (1993) 1.01
Polymerase chain reaction and viral culture techniques to detect HSV in small volumes of cerebrospinal fluid; an experimental mouse encephalitis study. J Virol Methods (1989) 1.01
Prospective analysis of falls in dominant ataxias. Eur Neurol (2012) 1.00
CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging (2011) 1.00
Neurophysiological tests and neuroimaging procedures in non-acute headache: guidelines and recommendations. Eur J Neurol (2004) 1.00
Aetiology of uveitis in Sierra Leone, west Africa. Br J Ophthalmol (1996) 0.99
Long latency postural responses are functionally modified by cognitive set. Electroencephalogr Clin Neurophysiol (1991) 0.99
Walking patterns in Parkinson's disease with and without freezing of gait. Neuroscience (2011) 0.99
Pathogenesis of HIV and its implications for serodiagnosis and monitoring of antiviral therapy. J Virol Methods (1987) 0.99
Bone mineral density and vitamin D status in Parkinson's disease patients. J Neurol (2012) 0.99
Measurement of muscle fiber conduction velocity in humans: techniques and applications. J Clin Neurophysiol (1989) 0.98
Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Eur J Nucl Med Mol Imaging (2006) 0.98
Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov Disord (1999) 0.97
The influence of artificially increased hip and trunk stiffness on balance control in man. Exp Brain Res (2004) 0.96
Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther (2009) 0.96